aTYR PHARMA (ATYR) Other Working Capital Changes (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Other Working Capital Changes came in at -$191000.0 in Q1 2026, down 17.9% YoY from -$232646.6 in Q1 2025, and down 2.14% on a QoQ basis from -$187000.0 in Q4 2025.
aTYR PHARMA (ATYR) Other Working Capital Changes (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 8 years of Other Working Capital Changes data on file, last reported at -$191000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 17.9% year-over-year to -$191000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$740000.0 (down 208.33% YoY) and the FY2025 annual result came in at -$711000.0, down 107.29% from the prior year.
- Other Working Capital Changes fell to -$191000.0 in Q1 2026, from -$187000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $7.6 million in Q1 2024 to a low of -$4.8 million in Q3 2025.
- A 5-year average of -$273352.9 and a median of -$470000.0 in 2024 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes jumped 1239.91% — and 2023, when it slumped 1337.5%.
- Tracing ATYR's Other Working Capital Changes over 5 years: stood at $2.6 million in 2022, then plunged by 101.65% to -$43000.0 in 2023, then surged by 634.88% to $230000.0 in 2024, then slumped by 181.3% to -$187000.0 in 2025, then dropped by 2.14% to -$191000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$191000.0 (Q1 2026), -$187000.0 (Q4 2025), and -$183000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | aTYR PHARMA | 49.46 Mn | -7.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18,000.00 |
| Jun 30, 2026 | -18,000.00 |
| Jun 30, 2026 | -18,000.00 |
| Mar 31, 2026 | -91,000.00 |
| Mar 31, 2026 | -91,000.00 |
| Mar 31, 2026 | -91,000.00 |
| Dec 31, 2025 | -1.09 Mn |
| Dec 31, 2025 | -1.09 Mn |
| Dec 31, 2025 | -1.09 Mn |
| Sep 30, 2025 | -4.80 Mn |
| Sep 30, 2025 | -4.80 Mn |
| Sep 30, 2025 | -4.80 Mn |
| Jun 30, 2025 | 714,000.00 |
| Jun 30, 2025 | 714,000.00 |
| Jun 30, 2025 | 714,000.00 |
| Mar 31, 2025 | -2.16 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Dec 31, 2024 | -470,000.00 |
| Dec 31, 2024 | -470,000.00 |